Target intelligence / Profile preview

NIMA-related kinase 4 (NEK4)

Target
NEK4
Molecular classification
Enzyme, Serine/threonine protein kinase, Never in mitosis gene A (NIMA)-related kinase family
01

Overview

NIMA-related kinase 4 (NEK4) is a serine/threonine-protein kinase that belongs to the NIMA-related kinase family, playing a central role in the regulation of cell cycle progression, DNA damage response, mRNA splicing, and maintenance of cilium integrity[1][3][4]. NEK4 activity is required for normal entry into replicative senescence and cell cycle arrest in response to double-stranded DNA damage[3]. Genetic and molecular studies implicate NEK4 in multiple malignancies, including triple-negative breast cancer, where its depletion impacts cell proliferation—sometimes reducing and sometimes increasing proliferation depending on the cellular context[1][4]. NEK4 is also associated with ciliopathies and rare congenital disorders. The NEK family is under investigation as a source of new therapeutic targets and potential biomarkers in cancer and other diseases, though specific pharmacological inhibitors for NEK4 itself remain in early research phases[4].

Other names
Serine/threonine-protein kinase Nek4STK2NimA-related protein kinase 4NRK2pp12301Never in mitosis A-related kinase 4Serine/threonine-protein kinase 2Serine/threonine-protein kinase NRK2serine/threonine protein kinase-2
02

Mechanism of action

Inhibition of kinase activity for suppression of cell proliferation and alteration of cell cycle progression

03

Biological functions

Cell cycle regulationDNA damage responsemRNA splicingCilium integrityReplicative senescence
04

Disease associations

Cancer (triple-negative breast cancer, lung cancer, prostate cancer, colorectal cancer, hepatocellular carcinoma, and others)CiliopathyLeber congenital amaurosis 3
05

Safety considerations

Potential off-target effects on cell cycle regulation and DNA repairRisk of undesirable impact on cilia and replicative senescence pathways
06

Interacting drugs

Drugs targeting NEK family kinases are in development; specific NEK4 inhibitors are not yet clinically established
07

Biomarkers

Expression level of NEK4 as a biomarker in oncology for patient stratification and prognosis

Beyond the preview

Go deeper on NIMA-related kinase 4 (NEK4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIMA-related kinase 4 (NEK4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call